Eytan M. Stein, MD | Authors


Phase I Results for Enasidenib in AML

June 07, 2017

Eytan M. Stein, MD, internist, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of a phase I dose escalation and expansion study of enasidenib in mutant IDH-2 relapsed or refractory acute myeloid leukemia (AML) during the 2017 ASCO Annual Meeting.